Observational Study on One-Year Guselkumab Treatment Continuation in Adults with Psoriatic Arthritis

What this Trial Is About

This observational study evaluates how long adult patients with psoriatic arthritis continue treatment with guselkumab over a one-year period. Psoriatic arthritis is an inflammatory condition that affects joints in people who have psoriasis, a skin disease causing red, scaly patches. The study aims to better understand treatment persistence in real-world clinical practice settings. Participants with confirmed psoriatic arthritis receiving guselkumab as part of their routine medical care are observed. No study drug is provided instead, data collected during regular clinical visits are gathered over time. The study tracks patients starting guselkumab as either their first or subsequent disease-modifying antirheumatic therapy according to standard treatment guidelines. Throughout the study, researchers collect information on treatment continuation, disease activity scores, symptom changes, and patient-reported outcomes at baseline and regular intervals up to two years. Data include clinical assessments, medical history, medication details, and adverse events. The main measure is the proportion of participants still on guselkumab at one year, with further monitoring continuing to assess longer-term treatment and safety outcomes.

A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants